All times listed are Central Daylight Time. Program and Faculty are updated often – check back for the most up-to-date information. Click on session name to view session description and component talks.
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Systemic Lupus Erythematosus – Treatment Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Systemic Sclerosis & Related Disorders – Clinical Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
(TM01–TM11) Pediatric Thieves Market Poster
Location: Hall F1
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
(TM13–TM26) Adult Thieves Market Poster I
Location: Hall F1
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Vasculitis – ANCA-Associated Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0049: Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
0050: TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
0057: TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype
Location: Hall F1
Abstract Poster Presenter: Rajesh Singh, n/a – Arcus Biosciences, inc.
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0058: Training for increased inflammatory arthritis in mice is not modulated by type 1 interferon
Location: Hall F1
Abstract Poster Presenter: Richard Bell, PhD – Hospital for Special Surgery
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0059: Formyl Peptide Receptor 1 (FPR1) Influences Arthritis Severity in a Sex- and Compartment-Specific Manner
0061: IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
0065: Expression and Co-Localization of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues Precedes the Development of Cardiac Fibrosis in Collagen-Induced Arthritis
Location: Hall F1
Abstract Poster Presenter: Wenxian Zhou, BS – University of Nebraska Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0066: RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.
Location: Hall F1
Abstract Poster Presenter: Yidan Wang, MS – Northwestern University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0067: Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
0071: Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.
0072: Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
0073: HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Courtney Myhr, MS – University of Wisconsin-Madison
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0074: Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving ImmuneComplex Formation and Cellular Clearance
0076: Antibodies to Malondialdehyde-acetaldehyde Are Associated with Circulating Inflammatory Mediators During the Preclinical Stages of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Emma Weis, BS – University of Nebraska Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0077: Transformer-based multi-omics study identifies important role of glycine, serine and threonine metabolism pathway in rheumatoid arthritis complicated by anemia
Location: Hall F1
Abstract Poster Presenter: Fanxin Zeng, PhD – Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0078: Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
0084: Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts
Location: Hall F1
Abstract Poster Presenter: Keita Okamoto, MD;PhD – Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0085: Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Kensuke Suga, PhD – Cedars-Sinai Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0086: Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
Location: Hall F1
Abstract Poster Presenter: Kiana Chen, PhD – University of Rochester School of Medicine and Dentistry
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0087: Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms
Location: Hall F1
Abstract Poster Presenter: Laura Muñoz-Barrera, BSc – IMIBIC/Reina Sofia Hospital/University of Cordoba
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0088: Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Lyndsey Cole, MD – University of Colorado School of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0089: Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis
0092: SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging
0094: Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
0097: Aberrant Histone Marks Increase the Inflammatory Phenotype of Rheumatoid Arthritis Fibroblast-like Synoviocytes (RA FLS) by Suppressing NUB1 Induction
0146: Association Between Frailty and Delirium and Hospitalization Outcomes Among Older Adults with Rheumatic Diseases
Location: Hall F1
Abstract Poster Presenter: Bhavik Bansal, MBBS – UT Southwestern Medical Centre
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0147: Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations - PREST study
0155: Effect Modification of Cigarette Smoking on the Relationship between Post Traumatic Stress Disorder and Rheumatoid Arthritis Risk
Location: Hall F1
Abstract Poster Presenter: Kelsey Coziahr, MD – University of Nebraska Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0156: Heat Exposure and Acute Care Utilization among Individuals with Rheumatic Conditions: A Time Series Framework for Identifying Delayed Associations
Location: Hall F1
Abstract Poster Presenter: Leah Santacroce, MS – Brigham and Women's Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0157: Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
0158: Association Between Newer COVID-19 Vaccines and COVID-19 Related Hospitalizations Among People with Autoimmune Rheumatic Diseases in the U.S. National COVID Cohort Collaborative (N3C)
0163: Trends in hospitalization and outcomes among patients admitted with Adult-onset Still's disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)
0166: Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination
0169: The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
0173: Association Between the Ratio of Non-high-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol and All-cause Mortality Risk in Patients with Rheumatoid Arthritis: A Survival Analysis Based on NHANES Data
Location: Hall F1
Abstract Poster Presenter: Tingting Wang, n/a – Department of Rheumatology and Immunology, Dazhou Central Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0174: Genetic and Environmental Risk Factors and Incident Rheumatoid Arthritis
0197: Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
0200: Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
0201: Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
0203: Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
0205: Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Location: Hall F1
Abstract Poster Presenter: Laura Mas Sanchez, MD – Hospital Universitari i Politecnic La Fe
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0206: Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
0207: The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)
0208: Current practices and challenges in tuberculosis screening and preventive treatment among patients with rheumatic diseases: A multiregional physician survey in China
Location: Hall F1
Abstract Poster Presenter: Xu Wang, PhD – Peking Union Medical College Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0209: A Retrospective Safety Analysis Based on Platelets in Arthrocentesis and Joint Injections in Cancer Patients
0237: Monogenic autoinflammatory diseases and undefined autoinflammatory syndrome in Western Mediterranean adults: clinical, genetic, and therapeutic insights
Location: Hall F1
Abstract Poster Presenter: Alba Maria Torrat Noves, MD – Hospital Universitari i Politècnic La Fe de Valencia
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0238: Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Alessia Gatti, MD – University of Brescia
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0239: Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study
Location: Hall F1
Abstract Poster Presenter: Alireza Meysami – Henry Ford Health
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0240: Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
0241: Efficacy and Safety of JAK Inhibitors in Behçet's Syndrome: A Systematic Literature Review
Location: Hall F1
Abstract Poster Presenter: Bercemhan Sulu, MD (she/her/hers) – Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0242: Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept
0243: Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0244: Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0245: Predictors of Arterial Stiffness in Connective Tissue Diseases: Insights from the Lupus Extended Autoimmune Phenotype (LEAP) Cohort Study
Location: Hall F1
Abstract Poster Presenter: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0246: Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
0256: The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review
Location: Hall F1
Abstract Poster Presenter: Kari Falaas, MD – University of Minnesota
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0257: Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
0258: Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis
Location: Hall F1
Abstract Poster Presenter: Karyssa Stonick, BS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0259: Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
0262: Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders
0266: Chronic PPI Use Association with Development of Autoimmune Conditions: Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Nanuka Tsibadze, MD – Jefferson Health - Einstein
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0267: Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
Location: Hall F1
Abstract Poster Presenter: Nur Barlas, MD – Tulane University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0268: Multicenter study and literature review of JAK inhibitor treatment in refractory uveitis due to different immune-mediated inflammatory pathologies
0277: A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a Chimeric Degradation Activating Compound (CDAC), in Healthy Participants
Location: Hall F1
Abstract Poster Presenter: Vaibhav Mundra, MD – BeOne Medicines USA, Inc.
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0278: Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Location: Hall F1
Abstract Poster Presenter: Xiwei Yang, BA – Perelman School of Medicine, University of Pennsylvania
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0279: Assessment of Baseline igg4-rd Disease Characteristics and Impact upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Location: Hall F1
Abstract Poster Presenter: Yoshiya Tanaka, MD, PhD – University of Occupational and Environmental Health, Japan
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0280: Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.
0283: The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records
Location: Hall F1
Abstract Poster Presenter: Ana Valle, MD, MHS – Brigham and Women's Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0284: Glucocorticoid Tapering and Relapse Risk in Anti-ARS Antibody-Positive Myositis: A Retrospective Study in a Single-Center Cohort Treated with Immunosuppressants
Location: Hall F1
Abstract Poster Presenter: Ayaka Inoue, MD – Kakogawa Central City Hospital, Kakogawa, Japan.
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0285: Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study
0287: Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies
Location: Hall F1
Abstract Poster Presenter: DANIEL CARRILLO VAZQUEZ, MD, MSc – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0288: Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Didem Saygin, MD – Rush University Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0289: Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures
Location: Hall F1
Abstract Poster Presenter: Didem Saygin, MD – Rush University Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0290: Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
0294: Clinical relevance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies in patients with an underlying malignancy.
0295: Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
Location: Hall F1
Abstract Poster Presenter: Manali Sarkar, MBBS (she/her/hers) – Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India.
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0296: Aggregation of HARS1 and Internalized Antibodies in Muscle Biopsies of Patients with Antisynthetase Syndrome and anti-jo1(hars) Autoantibodies
0304: Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region
Location: Hall F1
Abstract Poster Presenter: Takahisa Gono, MD – Nippon Medical School Graduate School of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0305: From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
0338: Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis
0340: Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.
Location: Hall F1
Abstract Poster Presenter: Chern Lee Choy, MBBS – University Hospitals of Morecambe Bay NHS Foundation Trust
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0341: Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Location: Hall F1
Abstract Poster Presenter: Daniel Ramos Castro, MD – Hospital Universitari i Politecnic La Fe
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0342: Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0343: Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0344: Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
0345: Association Between Deprivation and Fracture Risk in a Regional UK Cohort
Location: Hall F1
Abstract Poster Presenter: Hashem Cheema, MBBS BSc MRCP – University Hospitals of Morecambe bay NHS foundation trust
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0346: Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
0347: Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Location: Hall F1
Abstract Poster Presenter: Kabyar Cho, MBChB, BSc – University Hospitals of Morecambe Bay NHS Foundation Trust
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0348: Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients
0354: Greater Neighborhood Walkability is Associated with Lower Incidence of Hip Fracture in Older, Community-dwelling Women in the United States: The Cardiovascular Health Study
0360: Assessing Content Validity of a New Questionnaire Evaluating Glucocorticoid Toxicity
Location: Hall F1
Abstract Poster Presenter: John Stone, MD, MPH – Massachusetts General Hospital , Harvard Medical School
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0361: Transition in Focus: Health Care Utilization and Disease Status in Youth with Connective Tissue Diseases— A Single-Center Experience in British Columbia, Canada
0370: Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
0375: Association of Glucocorticoid Toxicity Index Scores with Quality-of-life and Healthcare Resource Utilization at 6 Months in a Real-world Cohort of Individuals Receiving Glucocorticoids
0376: An Internet-delivered, Arthritis-tailored Cognitive Behavioral Therapy for Insomnia Program for People with Co-morbid Sleep Disturbance: Comparing Baseline Characteristics of Cannabis Users and Non-users
0380: Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
0381: Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies
0382: Preventative Health Screening Practices Among 666 Women with Systemic Rheumatic Diseases from the Hospital for Special Surgery Rheumatology Women’s Reproductive Health and Wellness Cohort: A Cross-Sectional Analysis
0408: Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0423: Macrophage activation syndrome-associated proteins and enhanced interferon gamma responsiveness characterize the plasma proteome of patients with Multisystem Inflammatory Syndrome in Children (MIS-C) in a pre-treatment replication single center cohort
0430: Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD
Location: Hall F1
Abstract Poster Presenter: ender terzioglu, MD – Akdeniz University Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0431: Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
0433: In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022
0434: The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice
Location: Hall F1
Abstract Poster Presenter: Meliha Kapetanovic, MD,PhD – Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0436: Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?
0439: Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort
0448: Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
Location: Hall F1
Abstract Poster Presenter: Ioannis Koulas, MD, MSc – Jacobi Medical Center/Albert Einstein College of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0449: Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
Location: Hall F1
Abstract Poster Presenter: Joel Kremer, MD – The Corrona Research Foundation
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0450: The Fibrosis-4 Index (FIB-4) Correlates with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis
0454: Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights
0455: Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active Psoriatic Arthritis
0460: The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Ryan Salama, BA – University of Minnesota Twin Cities
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0461: Right Diagnoses For the Wrong Reasons: Limitations of Current Large-Language Model based Agentic Frameworks for Screening of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Sarthak Verma, MD (he/him/his) – Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0462: Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?
0463: Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Location: Hall F1
Abstract Poster Presenter: Solana Cushing, BA – Icahn School of Medicine at Mount Sinai
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0464: Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty
Location: Hall F1
Abstract Poster Presenter: Solana Cushing, BA – Icahn School of Medicine at Mount Sinai
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0465: Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Location: Hall F1
Abstract Poster Presenter: Suchita Nety, PhD – Harvard Medical School
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0466: Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
Location: Hall F1
Abstract Poster Presenter: Tulsi Joishy, PhD – Vanderbilt University Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0467: A Machine Learning Classifier Leveraging anti-ra33, anti-pad4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA
0470: Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
0471: An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 anti-cd19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA Positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
Location: Hall F1
Abstract Poster Presenter: Ioanna Minopoulou, MD;MSc – Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0472: Detrimental Effects of Umbilical Cord Blood-derived Mesenchymal Stem Cells Intra-articular Injections on Pannus Invasiveness
0477: At the patient level, ultrasound evaluation during the follow up of rheumatoid arthritis does not modify radiographic evolution: a prospective, multicenter, randomized, pragmatic clinical trial (BCD study)
0478: Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
0481: Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
0486: Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0487: Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0488: Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
0490: Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted - DMARD in RA: A Systematic Review and Network Meta-analysis
Location: Hall F1
Abstract Poster Presenter: Jia Li, MD, PhD (she/her/hers) – Shanghai Jiao Tong University School of Medicine affiliated Renji hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0491: Association Of short Chain Fatty Acids and diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
0494: LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
0495: Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
0496: Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
0497: Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Location: Hall F1
Abstract Poster Presenter: Nariaki Hao, PhD – Graduate School of Medical and Dental Sciences, Niigata, Japan
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0498: Pharmacokinetic Similarity of DRL_AB, a Proposed Biosimilar Abatacept (Orencia®): Results from a Randomized, Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study in Healthy Subjects by the Intravenous Route.
0499: Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Location: Hall F1
Abstract Poster Presenter: Roy Fleischmann, MD – Metroplex Clinical Research Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0500: Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Location: Hall F1
Abstract Poster Presenter: Sama Hajizadeh, MD – Allegheny Health Network
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0501: Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety
0514: Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Location: Hall F1
Abstract Poster Presenter: Nicholas Bauer, BS – Oklahoma Medical Research Foundation
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0518: Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
0555: Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
Location: Hall F1
Abstract Poster Presenter: Joseph F. Merola, MD, MMSc – Department of Dermatology and Department of Medicine, UT Southwestern Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0556: Evaluating the Efficacy of Sulfasalazine Compared to Placebo in the Treatment of Psoriatic Arthritis in Adults: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0557: Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
0558: Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Location: Hall F1
Abstract Poster Presenter: Monica Leung, n/a – Johnson & Johnson, San Diego, CA, USA
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0559: Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
Location: Hall F1
Abstract Poster Presenter: Nehal Mehta, MD MSCE – The George Washington University School of Medicine and Health Sciences
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0560: Single Cell Sequencing Analysis of Tumour Necrosis Factor Inhibitor Drug Response Reveals Enrichment of Pro-inflammatory Pathway in Non-responders and Amino Acid Metabolic Pathways in Responders
0561: Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Location: Hall F1
Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0562: Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0563: Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0564: Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Location: Hall F1
Abstract Poster Presenter: Alice Gottlieb, MD, PhD – Department of Dermatology, UT Southwestern Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0565: Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
0567: Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Location: Hall F1
Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0568: Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
0570: Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
0571: Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Jaejoon Lee, MD;PhD – Samsung Medical Center, Sungkyunkwan University School of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0572: Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
0573: Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Location: Hall F1
Abstract Poster Presenter: Joseph F. Merola, MD, MMSc – Department of Dermatology and Department of Medicine, UT Southwestern Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0574: Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
Location: Hall F1
Abstract Poster Presenter: Joseph F. Merola, MD, MMSc – Department of Dermatology and Department of Medicine, UT Southwestern Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0575: Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients
0577: Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
0578: Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0579: Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0580: Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0581: Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0582: Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Location: Hall F1
Abstract Poster Presenter: Prabhu Vasantha Kumar, MD, DM – GKNM Hospitals & Research Institute, Coimbatore, Tamil Nadu, India
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0583: Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
0584: Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
0585: Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
0590: Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
0591: An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-world Clinical Practice
0592: An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-world Clinical Practice
0599: Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Aakash Patel, MD – Massachusetts General Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0600: Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
0601: Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
0602: Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
Location: Hall F1
Abstract Poster Presenter: Ami Vyas, PhD – University of Rhode Island
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0603: Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
Location: Hall F1
Abstract Poster Presenter: Amir Daneshvar, MD – University Hospitals Cleveland Medical Center/Case Western Reserve University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0604: Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus
0605: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
0611: Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0612: Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0614: Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
Location: Hall F1
Abstract Poster Presenter: Ileana Cecilia Reynosa Silva, MD – Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0615: Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
Location: Hall F1
Abstract Poster Presenter: Jacob Klein, MD – Ohio State University Wexner Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0618: Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study
Location: Hall F1
Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0619: Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Location: Hall F1
Abstract Poster Presenter: Luciana Seguro, MD, PhD – Hospital das Clínicas HCFMUSP, University of Sao Paulo
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0620: The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
0622: Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
0623: Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
0625: DNA methylation patterns in systemic lupus erythematosus associated with nephritis status
Location: Hall F1
Abstract Poster Presenter: Meghan Nelson, DO – National Institutes of Health
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0626: Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
Location: Hall F1
Abstract Poster Presenter: Nalani Sachan, PhD – NYU Grossman School of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0627: Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
Location: Hall F1
Abstract Poster Presenter: Omer Pamuk, MD – University Hospitals Cleveland Medical Center/ Case Western Reserve University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0628: Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Panagiotis Garantziotis, MD – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0630: Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus
0632: Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients with Systemic Lupus Erythematosus and Diabetes: A Propensity-Matched Retrospective Cohort Study
0634: Association of Lifestyle and Integrative Health Practices with Health-related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease
Location: Hall F1
Abstract Poster Presenter: Sarah Lieber, MD;MS – Hospital for Special Surgery
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0635: Comparison of the SARC-F with Objective Measures of Sarcopenia in Women with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Sarah Lieber, MD;MS – Hospital for Special Surgery
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0637: DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.
Location: Hall F1
Abstract Poster Presenter: Sundus Dwidar, B.S. – National Institutes of Health
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0638: Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era
Location: Hall F1
Abstract Poster Presenter: Takehiro Nakai, MD – St. Luke's International Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0639: Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients
0640: Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
0642: Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Location: Hall F1
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0644: Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Location: Hall F1
Abstract Poster Presenter: Joan Merrill, MD – Oklahoma Medical Research Foundation
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0645: Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-week Results from a Phase 3 Trial
0649: Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
0650: Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Location: Hall F1
Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0651: The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Braden Zeno, BS – Ohio State University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0652: Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
0653: In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at Their Clinical Dose Regimens
0654: Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Location: Hall F1
Abstract Poster Presenter: Ed Vital, MD – University of Leeds
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0655: Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Location: Hall F1
Abstract Poster Presenter: Eric Roberts, PhD, MPH – University of California, San Francisco
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0656: Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
0657: Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
Location: Hall F1
Abstract Poster Presenter: FNU Ruchi, MD – SUNY Upstate Medical University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0659: Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
0660: Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
0662: Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
0664: Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
0665: Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
0666: Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
0669: Clinical and Laboratory Factors Associated With Biopsy-Confirmed Antimalarial-Induced Cardiomyopathy
Location: Hall F1
Abstract Poster Presenter: Youngmin Kim, MD – Brigham and Women's Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0670: Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
0672: Determinants of Progressive Microstomia in Systemic Sclerosis: Insights from the GENISOS Cohort with a Focus on GI Involvement
Location: Hall F1
Abstract Poster Presenter: Ashish Balar, MBBS, MPH – The University of Texas Health Science Center Houston
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0673: Association Between Vasoactive-vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence from a EUSTAR Study
0674: Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis
Location: Hall F1
Abstract Poster Presenter: Crystal Cheung, MS – Yale University School of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0675: Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.
0676: Engineered glove for the objective assessment of hand dexterity in patients with systemic sclerosis: correlations with clinical features, nailfold videocapillaroscopy, and high frequency skin ultrasonography
Location: Hall F1
Abstract Poster Presenter: Elvis Hysa, MD – University of Genova
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0677: Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
0678: Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
Location: Hall F1
Abstract Poster Presenter: Wolfgang Merkt, MD – University Hospital Düsseldorf
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0679: Inhibition of TGFb3 in Systemic Sclerosis Patients Does Not Result in TGFb Pathway Modulation in Skin Biopsies or Circulation
0681: Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis
0686: Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Location: Hall F1
Abstract Poster Presenter: Ariane Herrick, MD – The University of Manchester, UK
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0687: Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification
Location: Hall F1
Abstract Poster Presenter: Arjun Mahajan, MS – Harvard Medical School
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0688: Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Location: Hall F1
Abstract Poster Presenter: Benjamin Chaigne, MD, PhD – Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0689: Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment
0690: Quantitative 18F-FDG PET-CT of the lungs detects treatment induced changes in patients with early severe diffuse cutaneous systemic sclerosis and interstitial lung disease
Location: Hall F1
Abstract Poster Presenter: Bo Broens, MD – Amsterdam UMC
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0691: Association of Elevated Platelets and CRP with Severe Disease and Poor Survival in Systemic Sclerosis
0692: A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with No Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
0693: Impact of X Chromosome Dosage on the Development of Diffuse and Limited Systemic Sclerosis in Klinefelter, Triple X, and Turner Syndromes: A Multicenter Cohort Study
Location: Hall F1
Abstract Poster Presenter: Hanieh Akbari, MD – Jefferson Einstein Montgomery Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0694: Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
0705: Multimodal Imaging Evaluation of Patients with Raynaud's Phenomenon meeting the Criteria for "Early" Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
0708: Association of Choroidal Sub-foveal Thickness with Skin Manifestations and Serum Monocyte HDL Ratio in Patients with Systemic Sclerosis-a Case Control Study
0709: Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
Location: Hall F1
Abstract Poster Presenter: Tracy Frech, MD, MS – Vanderbilt University Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0710: Vascular Events in Systemic Sclerosis Patients with Anti-Phospholipid Antibodies
Location: Hall F1
Abstract Poster Presenter: Vivian Shing, BS – Mayo Clinic Alix School of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0731: The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Jean-Paul Makhzoum, MD, FRCPC, MSc, FACP – Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0732: Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)
0739: Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Location: Hall F1
Abstract Poster Presenter: CARMEN SECADA-GÓMEZ, MD – HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0740: Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Location: Hall F1
Abstract Poster Presenter: CARMEN SECADA-GÓMEZ, MD – HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0741: Characteristics of African American vs. Non-African American Patients with Giant Cell Arteritis: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Dana Nachawati, DO – University Hospitals Cleveland Medical Center/Case Western Reserve University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0742: Exploring Racial Variation in the Clinical Manifestations of Giant Cell Arteritis: A Retrospective Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Dana Nachawati, DO – University Hospitals Cleveland Medical Center/Case Western Reserve University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0743: Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
0760: The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Sema Kaymaz-Tahra, MD – Bahcesehir University Faculty of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0760: The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Sema Kaymaz-Tahra, MD – Bahcesehir University Faculty of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0762: Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers
Location: Hall F1
Abstract Poster Presenter: Verena Schoenau, MD (she/her/hers) – - Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany.
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0763: Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience
Location: Hall F1
Abstract Poster Presenter: Wendy Perdomo, MD – Thomas Jefferson University Hospital
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0764: Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery - Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-
0769: Increased Gait Variability at Preferred Walking Speeds is Associated with Increased Physical Activity Measures in People with Knee Osteoarthritis
0770: Interrelationships of Depression, Pain, and Gait Mechanics and their Associations with Physical Activity Levels Among People with Knee Osteoarthritis
0233: Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis
0219: Increased Engagement With the RISE Registry Clinician Dashboard Is Associated With Improving Performance on Some but Not All Rheumatology Quality Measures
0393: Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis
0442: Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Location: Hall F1
Abstract Poster Presenter: Charis Meng, MD – Hospital for Special Surgery
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0506: Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren's Disease Using High-content Human Proteome Arrays
Location: Hall F1
Abstract Poster Presenter: A. Darise Farris, PhD – Oklahoma Medical Research Foundation
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0553: Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
Location: Hall F1
Abstract Poster Presenter: Zeyu Tang, MD – Yale School of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0018: Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases
0223: Timely Dermatologic Diagnosis and Management Changes in Systemic Collagen Vascular Diseases: Experiences from the Rheumatology-Dermatology Combined Clinic
Location: Hall F1
Abstract Poster Presenter: Jeanie Lee, MD – Montefiore Einstein Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0306: Direct Assessment of Intestinal Permeability as a Risk Factor for Multiple Joint Osteoarthritis in Community Cohorts of Humans and Pet Dogs
0538: Development of an Artificial Intelligence Tool for Lesion Detection in Axial Spondyloarthritis patients with Active Sacroiliitis on Magnetic Resonance Imaging
0013: Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Location: Hall F1
Abstract Poster Presenter: Minyun Zhou, PhD – Simcere Pharmaceutical Group
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0021: Doctis: A Single Cell Rna-seq Atlas of Drug Response to Targeted Therapies
Location: Hall F1
Abstract Poster Presenter: Antonio Julià, PhD – Vall d'Hebron Hospital Research Institute
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0127: Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease
0177: Artificial Intelligence in Adult and Paediatric Rheumatology Practice and Research: Pilot Results from an International Survey
Location: Hall F1
Abstract Poster Presenter: Ana Isabel Rebollo-Giménez, MD – Department of Rheumatology, Gregorio Marañón University Hospital, Gregorio Marañón Health Research Institute
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0224: Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis
Location: Hall F1
Abstract Poster Presenter: John Hickernell, MD – Loyola University Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0308: Artificial Intelligence Assisted Extraction of Patient-reported Pain Outcomes in Osteoarthritis Using Prompt Engineering of Large Language Models
Location: Hall F1
Abstract Poster Presenter: Bella Mehta, MD, MS, MBBS – Hospital for Special Surgery, Weill Cornell Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0409: Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0524: Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors
Location: Hall F1
Abstract Poster Presenter: Servet Akar, MD – Izmir Katip Çelebi University School of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0719: A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis
0724: Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis - Results from Real-World Data
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0016: Pharmacology Analyses of Sail’s In Vivo hCD19 CAR-T Product Reveal Mechanistic Insights Underlying its Optimal Dose Efficiency Profile in Both Healthy Donors and SLE Patient Samples
0210: Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
Location: Hall F1
Abstract Poster Presenter: Akhil Sood, MD – Stanford University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0218: Creating an EHR Lupus Outreach Workbench to Address Care Gaps
Location: Hall F1
Abstract Poster Presenter: Christie Bartels, MD, MS – University of Wisconsin School of Medicine and Public Health
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0311: Time series analysis of continuous accelerometry data to determine the impact of symptomatic multiple joint osteoarthritis (MJOA) in the naturally occurring canine model
Location: Hall F1
Abstract Poster Presenter: Liubov Arbeeva, MSc – University of North Carolina, Chapel Hill
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0411: Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0513: Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
0545: Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis
0723: Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab
Location: Hall F1
Abstract Poster Presenter: Michele Moretti, MD – University of Pisa, Rheumatology Unit
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0031: Meta-Analysis of Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Location: Hall F1
Abstract Poster Presenter: Kevin Bu, MD;PhD – Icahn School of Medicine at Mount Sinai
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0140: Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study
0532: Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
0711: Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
0319: Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Danielle Madison, DO – Lakeland Regional Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0389: An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis
Location: Hall F1
Abstract Poster Presenter: Nicolino Ruperto, MD, MPH – Università Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0540: Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
Location: Hall F1
Abstract Poster Presenter: Manouk de Hooge, PhD – Ghent University Hospital & Leiden University Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0728: Incidence and Clinical Characteristics of ANCA-Associated Vasculitis: A Nationwide Study in Spain
0045: Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
0317: “No Matter How Great My Doctor Is, He Hasn't Had a Knee Replacement, He Doesn't Understand All That Pain” Program Evaluation of the Moving Well Peer Coach Intervention for Total Knee Replacement
0713: Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
Location: Hall F1
Abstract Poster Presenter: Adil Vural, MD – Cleveland Clinic
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0014: NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Location: Hall F1
Abstract Poster Presenter: Mira Tohmé, PhD – nkarta therapeutics
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0046: Association of Genetic Variation inxist and Ftx with Susceptibility to Female-biased Systemic Autoimmune Disease
0136: Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
Location: Hall F1
Abstract Poster Presenter: Ritesh Kumar Mishra, MD – JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0187: Message Testing in Online Recruitment Advertisements for a National Rheumatoid and Psoriatic Arthritis Study
0225: Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Location: Hall F1
Abstract Poster Presenter: Juan Schmukler, MD – Rush University Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0309: A Composite Cumulative Cartilage Damage Metric Predicts Incident Symptomatic Knee OA: Data from the Osteoarthritis Initiative
0006: QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
0026: Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis
Location: Hall F1
Abstract Poster Presenter: Andrea-Hermina Györfi, MD – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University.
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0123: Prognosis of Cardiac Involvement in Antiphospholipid Syndrome
0314: What changes in quality of life can be observed in patients with knee or hip OA prior to total hip or total knee replacement surgery ? data from the KHOALA cohort
0396: Quantifying Burden of Uveitis Care for Pediatric Uveitis Patients and Caregivers
Location: Hall F1
Abstract Poster Presenter: Catherine Lavallee, MD – St. Christopher's Hospital for Children
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0519: A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren's Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Shu Liu, n/a – Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0547: Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
0125: The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0185: Promoting Health Services Research Rigor and Reproducibility using CodeMapper: A novel tool for harmonization, collaboration, and precision
Location: Hall F1
Abstract Poster Presenter: Emily Holladay, MPH – University of Alabama at Birmingham
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0226: Integration of the 5Ms of Geriatrics in a Novel Geri-Rheumatology Clinic
0398: Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Location: Hall F1
Abstract Poster Presenter: Christina Gulla, DO – Hackensack University Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0552: Radiographic Sacroiliitis Progression in Psoriatic Arthritis
0730: Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
0100: Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Location: Hall F1
Abstract Poster Presenter: Beatriz Vellón-García, MSc – Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0109: Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
0211: Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration
0427: Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts
0523: SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
0616: Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study
0726: Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
0320: Transcriptomic profiling of the skeletal muscle of knee OA patients uncovers elevated glucocorticoid and GABA signaling as mediators of skeletal muscle dysfunction in advanced disease
0133: Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Location: Hall F1
Abstract Poster Presenter: Maria Tektonidou, PhD – National and Kapodistrian University of Athens
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0310: Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO
0313: People with Knee Osteoarthritis Infrequently Seek Medical Care for Arthritis, Even Those With Severe Disease
Location: Hall F1
Abstract Poster Presenter: Shunshun Yan, MD – Baylor College of Medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0390: Radiographic Assessment in Juvenile Spondyloarthritis: Evaluating the axJSpA Criteria Using Radiographs Alone Versus MRI
Location: Hall F1
Abstract Poster Presenter: Pamela Weiss, MD – Childrens Hospital of Philadelphia
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0507: Diagnostic performance of the lacrimal and salivary gland ultrasound in patients with primary Sjogren's disease of recent onset versus sicca controls.
0391: Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care
0118: Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome
Location: Hall F1
Abstract Poster Presenter: Ecem Sevim, MD – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0402: Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
0033: Development and Internal Validation of Two Human Leukocyte Antigen Genetic Risk Scores for Predicting Rheumatoid Arthritis Progression and Anti-Citrullinated Protein Antibody-Positivity
0536: Can achieving sustained low disease activity through treat-to-target management arrest enthesiophyte progression in psoriatic arthritis? A two-year prospective study using high resolution peripheral quantitative computed tomography
Location: Hall F1
Abstract Poster Presenter: Isaac Cheng, PhD – The Chinese University of Hong Kong
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0037: A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/differentiation Factor 15 (GDF-15) Improves Prediction of All-cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
0124: Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Location: Hall F1
Abstract Poster Presenter: Haoyu Pan, MD – Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0307: Cytokine Profiling of Molecular Endotypes of Knee Osteoarthritis: Insights from the IMI-APPROACH cohort
0539: Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort
Location: Hall F1
Abstract Poster Presenter: Liese de Bruin, MSc – Leiden University Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0025: Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Location: Hall F1
Abstract Poster Presenter: Elio Carmona, PhD – University of Pittsburgh, School of medicine
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0139: When One Isn't Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
0312: Efficacy and Safety of Tocilizumab in Children with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Rida Ul Jannat, n/a – Wake Forest University, Winston Salem North Carolina
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0424: Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India
0528: Apolipoprotein A1 and B Levels Indicate Specific Lipid Changes in Early Treatment Naïve Psoriatic Arthritis and Correlate with 1-year Disease Activity
0009: MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Location: Hall F1
Abstract Poster Presenter: Marisa Peluso, MS – Monte Rosa Therapeutics
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0035: Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
0221: A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-centered National Rheumatoid Arthritis Network
Location: Hall F1
Abstract Poster Presenter: Grant Cannon, MD – University of Utah and Salt Lake City VA
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0333: Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees
0533: Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission
Location: Hall F1
Abstract Poster Presenter: Avarna Agarwal, MD (she/her/hers) – Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0631: Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow up in an Inception Cohort of SLE (INSPIRE) from India
0418: Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis
0397: Paediatric uveitis - Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom
0546: Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
0387: Association Between Juvenile Arthritis and Physical Activity Levels in U.S. Children: A Cross-sectional Study Using the 2016–2021 National Survey of Children’s Health
0416: Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting
0428: The OMERACT Juvenile Idiopathic Arthritis MRI Score for Active and Structural Lesions in the Sacroiliac Joints: Development and Validation in Two Longitudinal Cohorts
0114: A Rare Variant in the extl3 Gene Is Associated with Altered Wnt Signaling Pathway in a Novel Mouse Model of Axial Spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0144: Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
0186: Validation of Asynchronous Telehealth Visit for Adults and Children with Inflammatory Arthritis and Feasibility of Applying Thermal Imaging during Visits
0222: Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey
0422: Clinical Outcomes of Ultrasound Guidance for Corticosteroid Injections of the Ankle and Midfoot Joints and Tendon Sheaths in Children with Juvenile Idiopathic Arthritis
0508: Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
0542: Transition from Psoriasis to Psoriatic Arthritis: Does Family History Influence the Time to Onset of Arthritis in Psoriasis Patients?
Location: Hall F1
Abstract Poster Presenter: Marta Flores, MD – University of Cordoba
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0429: Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Location: Hall F1
Abstract Poster Presenter: Xuemei Tang, MD, Professor, Chief Physician – Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0419: Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results
0220: National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration
0120: The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Location: Hall F1
Abstract Poster Presenter: Emre Sahin, MD – Hospital for Special Surgery
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0198: Variation in RA disease activity measure assessment and treatment change documentation in virtual vs in-office rheumatology visits
0325: Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)
0515: Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
Location: Hall F1
Abstract Poster Presenter: Nikolaos Marketos, MD, MSc, PhD – Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Greece
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0520: Implementation of Salivary Gland Ultrasound by General Radiology can Improve Detection of Glandular Inflammation in Patients with Sicca
Location: Hall F1
Abstract Poster Presenter: Stephanie Lee, MD (she/her/hers) – University of Pennsylvania and Children's Hospital of Philadelphia
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0529: Anti-peptidylarginine deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Ana-Maria Orbai, MD, MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0617: Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
0121: The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
Location: Hall F1
Abstract Poster Presenter: Emre Sahin, MD – Hospital for Special Surgery
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0181: Launch of the National Tele-Rheumatology Program (NTRP) to Expand Rheumatology Care to Rural Veterans
0217: Development of the American College of Rheumatology Implementation Guide for Integrating Patient Reported Systemic Lupus Erythematosus Quality Measures
0318: Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study
Location: Hall F1
Abstract Poster Presenter: Cheng Li, MBBS – Central south university
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0403: IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Ekaterina Alexeeva, MD, PhD – National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University)
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0509: Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
Location: Hall F1
Abstract Poster Presenter: R. Scofield, MD – Oklahoma Medical Research Foundation
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0526: Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
Location: Hall F1
Abstract Poster Presenter: Yoon-Jeong Oh, MD – Uijeongbu Eulji Medical Center
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0720: Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials
0043: Single-cell and Spatial Transcriptomic Profiling of Muscle Reveals Inflammatory Mechanisms in Anti-glycyl tRNA Synthetase Syndrome
Location: Hall F1
Abstract Poster Presenter: Takuya Harada, MD – Japan Institute for Health Security
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0105: Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
0183: Optimizing the Clinical Application of Rheumatology Guidelines Using Large Language Models: A Retrieval-Augmented Generation Framework Integrating EULAR and ACR Recommendations
0722: Estimating two-year risk of relapse in individuals with ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids
0101: Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Benjamin Cai, BS – Frazer Institute, The University of Queensland
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0137: Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
Location: Hall F1
Abstract Poster Presenter: Ritesh Kumar Mishra, MD – JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0184: Neurocognitive Complications of Lupus: A Multidisciplinary Program Model for Advanced Diagnostics, Management, and Clinical Research
0327: Structural Severity Assessment of Hand Osteoarthritis Using Radiomic Analysis: Correlation with the Kellgren-Lawrence Score – Results from the DIGICOD Cohort
